Quantification of Lung PET Images:Challenges and Opportunities by Chen, Delphine L et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quantification of Lung PET Images
Citation for published version:
Chen, DL, Cheriyan, J, Chilvers, ER, Choudhury, G, Coello, C, Connell, M, Fisk, M, Groves, AM, Gunn, RN,
Holman, BF, Hutton, BF, Lee, S, MacNee, W, Mohan, D, Parr, D, Subramanian, D, Tal-Singer, R,
Thielemans, K, van Beek, EJR, Vass, L, Wellen, JW, Wilkinson, I & Wilson, FJ 2017, 'Quantification of Lung
PET Images: Challenges and Opportunities' Journal of Nuclear Medicine, vol. 58, no. 2, pp. 201-207. DOI:
10.2967/jnumed.116.184796
Digital Object Identifier (DOI):
10.2967/jnumed.116.184796
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Nuclear Medicine
Publisher Rights Statement:
© by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Deposit permitted by the publisher.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
C O N T I N U I N G E D U C A T I O N
Quantification of Lung PET Images: Challenges
and Opportunities
Delphine L. Chen1, Joseph Cheriyan2,3, Edwin R. Chilvers2, Gourab Choudhury4, Christopher Coello5, Martin Connell4,
Marie Fisk2, Ashley M. Groves6, Roger N. Gunn5,7, Beverley F. Holman6, Brian F. Hutton6, Sarah Lee8,
William MacNee4, Divya Mohan9, David Parr10, Deepak Subramanian11, Ruth Tal-Singer9, Kris Thielemans6,
Edwin J. R. van Beek4, Laurence Vass2, Jeremy W. Wellen12, Ian Wilkinson2,3, and Frederick J. Wilson13
1Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri; 2Department of Medicine,
University of Cambridge, Cambridge, United Kingdom; 3Cambridge University Hospitals NHS Foundation Trust, Cambridge, United
Kingdom; 4Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom; 5Imanova Ltd., London,
United Kingdom; 6Institute of Nuclear Medicine, University College London, London, United Kingdom; 7Department of Medicine,
Imperial College London, London, United Kingdom; 8Medical Image Analysis Consultant, London, United Kingdom; 9Clinical
Discovery, Respiratory Therapy Area Unit, GlaxoSmithKline R&D, King of Prussia, Pennsylvania; 10University Hospitals Coventry
and Warwickshire, Coventry, United Kingdom; 11Derby Teaching Hospitals NHS Foundation Trust, Derby, United Kingdom;
12Worldwide Research and Development, Pfizer, Inc., Cambridge, Massachusetts; and 13Experimental Medicine Imaging,
GlaxoSmithKline, Stevenage, United Kingdom
Learning Objectives: On successful completion of this activity, participants should be able to (1) describe the methods that have been used to quantify 18F-
FDG uptake in the lungs using dynamic PET; (2) discuss the interpretation of the outcomes from these methods; and (3) provide suggested considerations on
quantification of 18F-FDG uptake in the lungs for future studies.
Financial Disclosure: Dr. Cheriyan’s salary is funded in part by GlaxoSmithKline for clinical research. Dr. Lee is a consultant to GlaxoSmithKline. Drs. Mohan
and Tal-Singer and Mr. Wilson are employees and shareholders of GlaxoSmithKline. Mr. Wilson was previously a consultant to ECNP R&S, GlaxoSmithKline,
IPPEC, King’s College London, Lundbeck A/S, Mentis Cura Ehf, and Pfizer, Inc., and has received travel expenses as a guest speaker from Orion Pharma Ltd.
Dr. Wellen is an employee and shareholder of Pfizer. Dr. Gunn is a consultant for Abbvie, Biogen, GlaxoSmithKline, UCB, Roche, and Genentech, S.A. Drs.
Groves, Holman, Thielemans, and Hutton have research grants from GlaxoSmithKline and receive funding from the National Institute for Health Research
University College London Hospitals Biomedical Research Centre. Dr. Chen receives funding from the National Institutes of Health (R01 HL121218). Drs.
Cheriyan and Wilkinson receive funding from the National Institute of Health Research (NIHR) Cambridge Comprehensive Biomedical Research Centre. Dr.
Gunn is an employee of Imanova and Imperial College London. Dr. Coello is an employee of Imanova. The authors of this article have indicated no other
relevant relationships that could be perceived as a real or apparent conflict of interest.
CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians.
SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit
commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through
the SNMMI website (http://www.snmmilearningcenter.org) through February 2020.
Millions of people are affected by respiratory diseases, leading to a
significant health burden globally. Because of the current insuffi-
cient knowledge of the underlying mechanisms that lead to the
development and progression of respiratory diseases, treatment
options remain limited. To overcome this limitation and understand
the associated molecular changes, noninvasive imaging techniques
such as PET and SPECT have been explored for biomarker
development, with 18F-FDG PET imaging being the most studied.
The quantification of pulmonary molecular imaging data remains
challenging because of variations in tissue, air, blood, and water
fractions within the lungs. The proportions of these components
further differ depending on the lung disease. Therefore, different
quantification approaches have been proposed to address these
variabilities. However, no standardized approach has been devel-
oped to date. This article reviews the data evaluating 18F-FDG PET
quantification approaches in lung diseases, focusing on methods to
account for variations in lung components and the interpretation of
the derived parameters. The diseases reviewed include acute re-
spiratory distress syndrome, chronic obstructive pulmonary dis-
ease, and interstitial lung diseases such as idiopathic pulmonary
fibrosis. Based on review of prior literature, ongoing research, and
discussions among the authors, suggested considerations are pre-
sented to assist with the interpretation of the derived parameters
from these approaches and the design of future studies.
Key Words: pulmonary; lung inflammation; molecular imaging;
positron emission tomography
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Respiratory diseases are a significant global health burden that
affect millions of people (1,2). However, treatment options remain
limited because pathogenic mechanisms remain poorly under-
stood. The clinical manifestations and severity of lung diseases
vary significantly, and the number of clinical biomarkers available
to identify aggressive disease phenotypes with accelerated pro-
gression is limited. Furthermore, 50% of drugs fail in phase III
trials because of lack of demonstrable efficacy, and respiratory
drugs are often the costliest to develop (1,3,4). These facts
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highlight the need for quantitative biomarkers to select appro-
priate therapeutic targets and assess the efficacy of novel respi-
ratory therapies.
The U.S. Food and Drug Administration defines a biomarker
as “a defined characteristic that is measured as an indicator of
normal biologic processes, pathogenic processes, or responses to
an exposure or intervention, including therapeutic interventions”
(5). Traditional clinical measures, such as global lung function,
reflect disease severity rather than disease activity. Because in-
flammation is commonly associated with respiratory diseases,
robust molecular biomarkers of pulmonary inflammation might
be applied in multiple ways to aid the development of effective
therapies, including in early-phase clinical pharmacodynamic stud-
ies of antiinflammatory therapies, as a complement to structural
imaging and functional spirometry measures in phenotyping pa-
tients who may benefit from more intensive therapy or earlier lung
transplantation, and as a tool to improve our understanding of the
pathogenic mechanisms of these complex lung diseases.
Molecular imaging approaches such as PET and SPECT
might meet the need for noninvasive biomarkers of lung disease
(6). Because inflammatory cell recruitment leads to increased
glucose utilization in the lungs, 18F-FDG PET has been widely
explored as a biomarker of pulmonary inflammation (7–11).
However, standardized quantification approaches are lacking.
To isolate the 18F-FDG uptake by parenchymal and immune
or inflammatory cells, different methods have been proposed
to account for regional variations in the fractions of air, blood,
and water, which can vary dramatically with each lung disease.
Accounting for these variations will apply equally to new mo-
lecular imaging tracers that can measure the activity of specific
aspects of lung inflammation or other processes such as fibrosis
or endothelial cell activity, as recently reviewed (12,13).
A primary goal for this field is to standardize these approaches
for each lung condition. Variability in measured tracer uptake also
arises from respiratory motion and differences in reconstruction
approaches, among other factors, but these technical issues will be
discussed only briefly. Quantification methods for 18F-FDG lung
imaging will be reviewed as it is the most widely studied PET
tracer to date and serves as a model for all PET and SPECT tracers
used for lung imaging.
CLINICAL APPLICATIONS INVESTIGATED WITH 18F-FDG
PET IMAGING
Inflammation characterizes several lung diseases, including
pneumonia, cystic fibrosis, chronic obstructive pulmonary disease
(COPD), acute respiratory distress syndrome (ARDS), asthma,
and interstitial lung diseases such as idiopathic pulmonary fibrosis
(IPF), among others (7,8,10,11,14–25). Because ARDS, COPD,
and IPF can cause significant variability in the amounts of air,
blood, and water in the lungs (Fig. 1), we will focus our methodology
discussion on these diseases. ARDS is characterized by persistent
pulmonary neutrophilic inflammation, edema, and pulmonary hem-
orrhage. These can lead to signal from unbound 18F-FDG in the
increased blood and water fractions as well as specific trapping in
neutrophils (26). In COPD, increased numbers of lung neutrophils
and macrophages (1,27–30) would be expected to increase the 18F-
FDG signal despite a reduction in measured 18F-FDG due to larger
air fractions and reduced blood volumes as a result of emphysema
(31). Finally, IPF is characterized by interstitial pneumonia along
with fibrosis in a characteristic subpleural pattern of distribution,
leading to reduced air, increased fibrosis, and alterations in blood
volume depending on the stage of fibrosis (32). These differences in
pathobiology highlight the need to account for the changes in the
cellular and fluid composition in the lungs when interpreting any
increased lung 18F-FDG uptake. Exacerbations also represent a con-
founding factor leading to increased lung inflammation and 18F-
FDG uptake; consequently, most studies have been performed in
the clinically stable state.
ANALYSIS METHODS AND THEIR APPLICATIONS IN
LUNG DISEASES
Quantification Approaches for 18F-FDG
Overview. The 18F-FDG signal within each PET voxel or pre-
defined region of interest (ROI) in the lungs represents the con-
tribution of activity in parenchymal (i.e., alveolar), airway wall,
vascular wall (e.g., endothelial), and immune cells (known collec-
tively in this paper as lung cells), as well as blood and water (i.e.,
extracellular fluid). Several factors can degrade the lung cell signal
within each voxel, including normal respiratory motion and the
presence of air that causes partial-volume averaging within each
voxel. Furthermore, the contribution of
signal from compartments without spe-
cific binding, such as blood or water in
the lungs, further reduces the signal spec-
ificity. The ideal parameter for quantify-
ing 18F-FDG lung uptake would reflect
metabolic activity only from the cells
thought to contribute to lung disease pro-
gression, namely the lung cells, to deter-
mine their pathogenic role. Therefore,
investigations have tested different meth-
ods to account for the 18F-FDG signal in
the blood and water and to remove the
impact of air fraction so that an outcome
measure specific to lung cells can be derived.
Although distinguishing the metabolism
of specific cell types, such as parenchy-
mal versus airway cells, would contribute
significantly to mechanistic studies of lung
disease, these quantification methods alone
cannot provide such information. However,
FIGURE 1. Variations in relative proportions of air, blood, lung tissue (parenchymal/airway and
endothelial cells) and immune cells, and water by lung disease. Proportions of blood and tissue in
brain are also shown for comparison.
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finding ways to measure lung cell metabolism specifically would
still help better characterize the role of lung cells in promoting
disease activity and progression.
The methods used to quantify 18F-FDG uptake in human studies
and that will be discussed in this review are summarized in Table
1. Compartmental modeling and Patlak graphical analysis have
been used to quantify 18F-FDG uptake from dynamic images.
The SUV, with or without dual-time-point imaging, and tissue-
to-blood ratio have been used for static images. Different ap-
proaches have been further applied to reduce the contribution of
background 18F-FDG signal from blood and water in the lungs as
well as to reduce partial-volume averaging from air in the ROI.
For example, kinetic modeling of dynamic PET data can deter-
mine the fractional blood volume, VB. PET and CT images have
been used to estimate the regional air fraction (VA). Using VA and
VB, the 18F-FDG uptake in everything that is not air or blood (i.e.,
lung cells and water) can be measured. These approaches are
reviewed below, followed by a discussion of their specific appli-
cations in ARDS, COPD, and IPF.
Kinetic Approaches. The Sokoloff method for quantifying 18F-
FDG uptake has served as the basis from which many of the
currently used kinetic quantification approaches are derived
(33,34). The method was originally developed for measuring brain
glucose metabolism, but a key assumption was that the blood
volume contribution was negligible relative to the brain parenchy-
mal signal. This was a recognized limitation for applying the
method in brain tumors, which have higher VB than normal brain,
necessitating the addition of a blood volume component to the
model (35). With VB estimated at approximately 0.16 in normal
lungs, the blood component has a more substantial effect, both in
TABLE 1
Summary of Human Studies Evaluating Quantitative Parameters for 18F-FDG Uptake in Lungs
Cohort Publication No. of subjects
Parameters derived
from PET imaging data
Correlative
data
ARDS Bellani et al., 2009 (19) 10 Patlak Ki PFTs
ARDS Bellani et al., 2011 (18) 13 Patlak Ki PFTs
ARDS/HV Grecchi et al., 2016 (20) 11/5 CM Ki, Patlak
Ki, SUV
None
ARDS model in HV Chen et al., 2006 (57) 18 Patlak Ki BAL neutrophil
3H-deoxyglucose
uptake
ARDS model in HV Chen et al., 2009 (56) 18 Patlak Ki BAL
Asthma–BC Taylor et al., 1996 (24) 9 Patlak Ki BAL
Asthma–BC Harris et al., 2011 (8) 6 Patlak Ki BAL
COPD/asthma/HV Jones et al., 2003 (10) 6/6/5 Patlak KiN 11C-PBR28 uptake,
PFT, sputum
COPD/HV/AATD COPD Subramanian et al., 2012 (17) 10/10/10 Patlak KiN PFTs
COPD Torigian et al., 2013 (39) 49 AFC SUV None
Cystic fibrosis/control Labiris et al., 2003 (16) 8/3 Patlak Ki Sputum
Cystic fibrosis/HV Chen et al., 2006 (7) 20/7 Patlak Ki, KiN BAL and PFTs
Cystic fibrosis Klein et al., 2009 (25) 20 SUV PFTs, WBC, CRP
Cystic fibrosis/control Amin et al., 2012 (15) 20/10 SUV PFTs, sputum,
CT metrics
HV Lambrou et al., 2011 (38) 12 AFC SUV None
Interstitial lung diseases,
including IPF
Groves et al., 2009 (11) 18 IPF/18 other
interstitial lung
diseases
SUV, TBR PFTs
IPF Umeda et al., 2015 (40) 50 Dual-time-point
SUV
CT-derived fibrosis
score, PFTs
IPF Holman et al., 2015 (21) 6 ABC Patlak Ki,
ABC CM Ki
None
IPF Win et al., 2012 (22) 13 AFC SUV None
IPF/control Win et al., 2014 (23) 25/25 AFC SUV None
Pneumonia/bronchiectasis Jones et al., 1997 (9) 5/5 KiN None
AATD5 α1 antitrypsin deficiency; ABC5 air- and blood-corrected; AFC5 air fraction–corrected; BAL5 bronchoalveolar lavage; BC5
bronchoscopic challenge; CM5 compartmental model; CRP5 C-reactive protein; HV5 healthy volunteer; KiN5 intercept-normalized Ki;
PFT 5 pulmonary function test; TBR 5 target-to-background ratio.
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terms of signal and in terms of fractional volume (Fig. 1). Therefore,
including VB in a lung compartment model is even more important.
Furthermore, the lung contains air, which is not the case for other
organs. Therefore, an equation that accounts for air and blood
fractions separately from the other lung components (Fig. 2) has
been published and applied in IPF and COPD (21,36):
CMðtÞ 5 VACAðtÞ1VBCBðtÞ1 ð1 2 VB 2 VAÞCT ðtÞ; Eq. 1
where, for a given ROI, CMðtÞ is the measured radioactivity con-
centration, CAðtÞ is the air concentration (which is negligible for
intravenously administered tracers such as 18F-FDG), CBðtÞ is the
blood concentration (derived from the dynamic images or blood
samples), and CTðtÞ is the concentration in lung cells and water
(i.e., everything that is not air or blood). VB can be estimated from
the compartment model. VA can be determined from the attenuation-
correction CT scan after downsampling to match the resolution of
the PET image (37,38). Therefore, this model enables isolation of
the signal from all nonair and nonblood lung components within
the ROI (CTðtÞ). However, when 1 2 VB 2 VA is less than 0.05
(such as in areas of severe emphysema), the accuracy of this
correction should be treated with caution (21).
The Patlak graphical analysis is derived from the general compart-
ment model for tracers that are irreversibly trapped in the target
tissue (39,40). This analysis provides 2 parameters: an estimate
of the influx rate constant Ki, a measure of 18F-FDG metabolism,
and the intercept, which approximates the distribution volume of
all the components of the reversible compartments. This method is
independent of the number of compartments. Intercept normaliza-
tion of the Ki has been attempted to account for the impact of air
on the measurement. However, from Equation 1, it can be shown
that the intercept-normalized Patlak Ki (KiN) is still influenced by
both VA and VB (34).
With these methods, after correcting for VA and VB, the esti-
mated 18F-FDG uptake comes from the lung cells and water (i.e.,
everything that is not air or blood). In interstitial lung diseases and
COPD, this is sufficient because the water fraction is small. How-
ever, in conditions with increased edema, such as ARDS, the water
fraction can be significant. Using independent measures of the
tissue fraction, VB, and wet-to-dry ratios (as a measure of water),
the normalized Ki determined by the Sokoloff model or a modified
4-compartment model that includes a compartment for nonspecific
trapping has been used to isolate the lung cell metabolic activity
(41–43). These studies confirm the importance of further evaluat-
ing modeling approaches that can account for the effects of air,
blood, and water together to measure the lung cell 18F-FDG signal
specifically.
Static Image Quantification Approaches. The SUV is the
concentration measured within a region or voxel normalized to
the patient weight and the injected activity. This is the most
common parameter measured clinically for PET because of its
simplicity, despite its dependency on metabolism in other organs,
body mass, and other confounding factors (44,45). The SUV is
also affected by air within ROIs. Normalizing it for the air fraction
will likely improve its accuracy as a reflection of lung cell meta-
bolic activity (38). Normalization for blood (such as the tissue-to-
blood ratio, as explored in a dog model of ARDS (46)) may further
improve the accuracy of VB; however, whether this approach is
comparable to correcting for VB as measured by kinetic analysis or
other imaging (such as 15O-CO scans) remains to be seen.
Other Contributions to Errors in 18F-FDG Quantification in the
Lungs. Reconstruction algorithms used to generate PET images
can have a significant impact on quantification accuracy, including
issues with nonlinearity and underconvergence when using iterative
algorithms (45). Most research in this area has focused on detecting
lung cancers, which have high signal relative to the lungs. There-
fore, further investigation is needed to optimize reconstruction per-
formance for the diffusely distributed, relatively low count activity
typically seen in the lungs.
Accurately matching tissue densities between PET and CT
images is also essential for accurate PET image attenuation
correction and VA correction. Gross spatial misregistration of the
measured attenuation map and PET activity distribution, which
frequently occurs at the diaphragm, is known to cause attenuation
correction artifacts (47,48). Additionally, changes in lung density
from normal respiration between the PET and CT acquisitions can
lead to errors in attenuation and VA correction, introducing addi-
tional variability to serial measurements and limiting accurate as-
sessment of the entire lung volume (49).
Improved methods for measuring changes
in lung density, as well as algorithms to re-
duce the impact of respiration (50,51) war-
rant further investigation to improve PET/CT
quantification accuracy in lung disease.
ARDS
The Patlak graphical analysis and com-
partmental model for quantifying lung
18F-FDG uptake have been evaluated most
extensively in animal and human models
of ARDS (41,46,52–57). In animal models
of ARDS, the Patlak Ki correlated with
3H-deoxyglucose uptake in airway cells
obtained by bronchoalveolar lavage (52),
and Ki normalized for tissue fraction (de-
termined independently by 13N-N2 scans)
correlated with lung neutrophil numbers by
histology (53). The Ki determined by the
Sokoloff model and by a 4-compartment
model that includes a water compartment,
FIGURE 2. Schematic of 3-compartment model describing kinetics of tracer in lung tissue (CT).
CB is concentration in blood, C1 is concentration in reversible compartment, C2 is concentration
in irreversible (trapped) compartment, CT is total tracer concentration in tissue, CM is measured
concentration in voxel or region, CA is concentration in air, VA is fractional air volume, VB is
fractional blood volume, and Ki is metabolic rate constant of 18F-FDG. Rate constants are rep-
resented as K1, k2, and k3. A full derivation has been previously published (34).
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when normalized for tissue fraction, blood fraction, and wet-to-
dry ratios determined independently, further demonstrated re-
gional differences in inflammation related to lung neutrophil num-
bers in correlating regions (42,43). In a healthy volunteer model of
endotoxin-induced acute lung inflammation, both Ki and KiN in-
creased, and both correlated weakly with neutrophil numbers (57).
Other lung cells also likely contributed to increased 18F-FDG
uptake after endotoxin instillation, as shown in mouse models
(58,59). These data demonstrate that increased 18F-FDG uptake,
quantified by both Ki and KiN, are associated with neutrophilic
inflammatory responses in these models.
Further validation with compartment modeling has also been
performed in ARDS animal models. Independent measures of
blood fraction and extravascular lung water obtained with 15O-CO
and 15O-H2O PET images correlated highly with 3-compartment-
model–derived estimates from the 18F-FDG data in a dog model
(46). The compartment model estimate of the Patlak Ki also cor-
related highly with the Patlak-determined Ki. Finally, the addition
of another compartment for extravascular lung water improved the
model fits for estimating lung 18F-FDG uptake in a sheep model,
supporting the applicability of this approach in ARDS (41). Hu-
man studies in patients with ARDS have used the Patlak Ki with-
out a correction for lung density or blood fraction but instead have
simply compared the Ki in normal versus dense tissue separately
across subjects (19,20).
COPD
Given the validation of CT for quantifying emphysema (60),
18F-FDG PET imaging holds great potential for providing addi-
tional inflammation-specific information. The KiN has been the
primary metric for quantifying 18F-FDG uptake in COPD and
asthma (10,17). Upper lung zone KiN correlates negatively with
pulmonary function and positively with CT-determined emphy-
sema severity (Fig. 3) (17). KiN may also correlate with a chronic
bronchitis phenotype (published in abstract form (61)), suggesting
the clinical relevance of this parameter. However, KiN is not in-
creased in subjects with stable asthma when compared with healthy
volunteers (10). Furthermore, no difference in the whole-lung Ki
was noted between COPD patients and healthy volunteers after
accounting for VA and VB using compartmental modeling (pub-
lished in abstract form (36)). The whole-lung SUV normalized for
the CT-determined air fraction has also been explored in patients
with COPD with emphysema but has not been compared with
tissue-based or clinical outcome measures (39). Finally, both infec-
tions and allergens frequently trigger asthma and COPD exacerba-
tions. KiN likely increases with both triggers, as has been shown in
lung transplant recipients with infection (62) and in subjects with
asthma after allergen challenge (8,24). Therefore, 18F-FDG PET
scans will need to be obtained during periods of clinical stability
to study the accuracy of different quantitative parameters for mea-
suring lung disease-specific inflammation. These studies together
highlight the need to continue defining the relationship of the dif-
ferent 18F-FDG PET quantitative parameters to outcome mea-
sures to determine which metrics are the best surrogate measures
of inflammation.
Interstitial Lung Diseases/IPF
Increased 18F-FDG uptake has been reported in the lungs of
patients with IPF using the SUVmax with or without correction
for the air fraction determined by CT (11,22,23,38). A study using
dual-time-point imaging further demonstrated that persistently in-
creased 18F-FDG uptake predicted a more rapid decline in lung
function and higher mortality in patients with IPF (40). Glucose
transporter 1 is expressed on erythrocytes and inflammatory cells
in lung sections from patients with IPF, with positive erythrocyte
but no inflammatory cell staining at sites of angiogenesis (63).
Catabolism genes associated with increased glucose metabolism
have increased expression by microarray analysis of human IPF
samples (64). These data together support the potential clinical
relevance of measuring 18F-FDG uptake in this disease. However,
a modeling analysis using Equation 1 actually showed decreased
18F-FDG uptake in the fibrotic areas of the lung compared with
areas that appeared normal by CT when accounting for VA and VB
(Fig. 4) (21). These findings still need to be compared with a
similar analysis of healthy lungs, but they highlight how these
modeling approaches can change the interpretation of 18F-FDG
uptake in IPF. Additionally, improved registration methods are
needed to accurately correct for attenuation changes in the periph-
ery, where fibrosis typically occurs. Collec-
tively, these results highlight the need for a
gold standard comparator to validate the
most relevant 8F-FDG parameters for IPF.
ISSUES AND SUGGESTED
CONSIDERATIONS
The methodologic issues discussed above
highlight the need for further studies to de-
termine and validate the most appropriate
approaches for lung imaging. Based on dis-
cussions among the authors, the following
summary statements were created to capture
the key aspects that should be considered
for future validation studies.
PET measurements of 18F-FDG concen-
tration in the lung are influenced by the
relative volumes of lung cells, air, blood,
and water.
It is essential to understand how the dif-
ferent methodologies account for the relative
FIGURE 3. Increased intercept-normalized Patlak Ki in upper lobes of lungs of COPD patients
correlates inversely with pulmonary function testing. (A) Three-dimensional imaging illustrating
predominantly apical distribution of pulmonary 18F-FDG uptake in patient with COPD. Maximum
signal of this color spectrum is represented by white, and minimum signal by black. (B) Relation-
ship between upper-zone 18F-FDG uptake and forced expiratory volume in 1 s (FEV1) (percentage
predicted) in COPD group (n 5 10). One-tailed P value is shown. (Reprinted with permission of
(17).)
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volumes of air, blood, and water when analyzing PET data to
obtain measurements of 18F-FDG concentration or kinetic parame-
ters in the lungs.
Relative air, blood, and water volumes vary within the lung
significantly among respiratory diseases and may depend on
disease severity. Without correction, these differences can poten-
tially cause significant variation in the quantified 18F-FDG PET
signal.
Although the KiN has been used as the endpoint in many pre-
vious publications on lung 18F-FDG uptake, it does not adequately
account for the impact of air and blood.
Compartmental modeling is a standard methodology for PET
image analysis that can be applied to lung 18F-FDG data. Using
CT data to estimate the air fraction and a kinetic model to account
for the blood fraction, it is possible to quantify the glucose met-
abolic rate for all remaining lung components (i.e., lung cells and
water) with 18F-FDG. The compartment model may need modifi-
cation to account for increased water (i.e., in ARDS). However, no
complete modeling solution that includes air, blood, and water
fraction corrections has yet been tested.
CONCLUSION
Investigating 18F-FDG uptake and kinetics in diffuse lung dis-
eases is becoming more common for phenotyping, monitoring
disease progression, and assessing the efficacy of novel targeted
treatments. For this purpose, ideally 18F-FDG uptake is measured
specifically in the lung cells that contribute to disease pathogen-
esis. However, regional variations in air, blood, and water fractions
can lead to inaccurate estimates of the lung cell tracer concentra-
tion. Without accounting for these effects, PET quantification ac-
curacy is compromised and could confound the correct interpre-
tation of the PET parameters in the context of the known biology.
To improve confidence in lung PET quantification, validation
of methods to account for air, blood, and water fractions using
independent techniques would be desirable. For example, the data
provided by serial 15O-CO, 15O-H2O, and dynamic 18F-FDG
imaging in the same imaging session would provide increased
confidence in the estimated blood and water volumes (37). Fur-
thermore, the reproducibility and reliability of these outcome
measures will need to be assessed in patients with a range of
diffuse lung diseases and in healthy controls. Finally, compar-
ison with clinical information, such as that from CT, lung tissue
sampling, or pulmonary function testing, can provide additional
context for correctly interpreting PET quantification parame-
ters. These are recommended as examples of future work to
promote the standardization of PET analysis methods for lung
imaging.
The conclusions laid out in this paper point to the need for a lung
imaging collaboration that encourages data and protocol sharing.
This will allow validation across the range of lung diseases to be
studied, ultimately producing a standardized acquisition and pro-
cessing methodology. Although not discussed as a focus of this
review, these collaborative efforts will also facilitate the evaluation
of the most appropriate reconstruction and motion correction
algorithms and imaging protocols to optimize lung PET imaging.
These efforts will ensure that accurate, reproducible, and clinically
interpretable images and estimated parameters can be produced
together with the requisite clinical validation before use in clinical
trials of established or novel therapies.
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